Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled time : 22:00 save search
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
Published: 2024-02-01 (Crawled : 22:00) - globenewswire.com
CABA | $13.96 -7.86% -8.52% 1.1M
|
Health Technology
|
| O: -2.09%
H: 12.16%
C: 9.33%
caba-201 fda drug granted treatment designation
Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System
Published: 2024-01-31 (Crawled : 22:00) - biospace.com/
BSX | $67.42 -0.8% -0.53% 5.9M
|
Health Technology
|
| O: 4.2%
H: 0.77%
C: -1.16%
fda approval system
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
Published: 2023-12-20 (Crawled : 22:00) - globenewswire.com
ANNX | $4.435 -3.27% -3.38% 1.4M
|
Health Technology
|
| O: 25.0%
H: 12.22%
C: 3.61%
anx007 fda global program
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
Published: 2023-12-20 (Crawled : 22:00) - prnewswire.com
CALT | News | $18.3 -2.35% -2.4% 6.1K
|
Health Technology
|
| O: 14.59%
H: 6.13%
C: -1.09%
tarpeyo fda nephropathy kidney approval treatment therapeutics
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
Published: 2023-12-15 (Crawled : 22:00) - globenewswire.com
ARQT A | $9.45 -7.81% -8.47% 2.9M
|
Health Technology
| Email alert
Add to watchlist
zoryve fda dermatitis treatment
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Published: 2023-12-15 (Crawled : 22:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
| Email alert
Add to watchlist
ALPMF | $9.594 43.47% 2.2K
|
Health Technology
| Email alert
Add to watchlist
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
| Email alert
Add to watchlist
padcev fda first approved bladder cancer treat advanced plus
FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis
Published: 2023-12-08 (Crawled : 22:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: 0.68%
H: 0.0%
C: 0.0%
ALPMF | $9.594 43.47% 2.2K
|
Health Technology
|
| O: -2.79%
H: 0.62%
C: 0.62%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -2.2%
H: 0.0%
C: -0.27%
cresemba fda children
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
Published: 2023-12-08 (Crawled : 22:00) - biospace.com/
BLUE | $0.9583 -0.52% -0.52% 6.5M
|
Health Technology
|
| O: 6.03%
H: 8.43%
C: -43.92%
fda disease approval cell
FDA Decisions: First Two Sickle Cell Gene Therapies Win Approval
Published: 2023-12-08 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 2.06%
H: 0.82%
C: 0.82%
PRGO | $29.94 -0.33% 0.0% 970K
|
Health Technology
|
| O: -0.13%
H: 1.02%
C: -2.82%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
fda first approval cell
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
Published: 2023-12-06 (Crawled : 22:00) - biospace.com/
ADAP | $0.8984 -8.98% -9.86% 3.3M
|
Health Technology
|
| O: 1.25%
H: 3.7%
C: -1.14%
fda license treatment application advanced submission
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K
|
Health Technology
|
| O: 3.87%
H: 0.0%
C: 0.0%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -3.37%
H: 4.51%
C: 4.51%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -4.92%
H: 1.48%
C: -0.21%
padcev fda license review bladder cancer treatment application grants
FDA Roundup: November 28, 2023
Published: 2023-11-28 (Crawled : 22:00) - prnewswire.com
SWTX | News | $42.48 -3.7% -3.84% 810K
|
Health Technology
|
| O: 2.64%
H: 11.94%
C: 6.05%
fda
FDA Roundup: November 17, 2023
Published: 2023-11-17 (Crawled : 22:00) - prnewswire.com
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
| Email alert
Add to watchlist
fda
Masimo W1™ Medical Watch Receives FDA 510(k) Clearance for Over-the-Counter and Prescription Use
Published: 2023-11-17 (Crawled : 22:00) - biospace.com/
MASI | $135.91 -0.52% -0.52% 240K
|
Health Technology
|
| O: 0.09%
H: 1.29%
C: 0.7%
fda clearance medical
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease
Published: 2023-10-31 (Crawled : 22:00) - globenewswire.com
CRSP M | $56.14 1.04% 1.03% 1.7M
|
Health Technology
|
| O: 11.61%
H: 1.63%
C: 0.69%
fda crispr disease cell meeting therapeutics
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
Published: 2023-09-28 (Crawled : 22:00) - biospace.com/
QNCX | $1.055 5.5% 5.21% 81K
|
Professional, Scientific, and T...
|
| O: -1.71%
H: 6.09%
C: 0.87%
fda lifted treatment
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda positive treatment meeting
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
Published: 2023-09-12 (Crawled : 22:00) - biospace.com/
RCKT M | $23.44 -1.01% -1.02% 550K
|
Health Technology
|
| O: 0.64%
H: 0.77%
C: -2.18%
fda disease rp-a501 pharmaceuticals trial phase 2
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
Published: 2023-09-06 (Crawled : 22:00) - biospace.com/
AMRX | $5.36 -1.83% -1.87% 840K
|
Health Technology
|
| O: 3.14%
H: 0.0%
C: -6.09%
fda approval injection
Boston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device
Published: 2023-09-06 (Crawled : 22:00) - biospace.com/
BSX | $67.42 -0.8% -0.53% 5.9M
|
Health Technology
|
| O: -0.34%
H: 2.03%
C: 1.39%
fda device approval
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.